Advertisement
Screener

NEXENTIS TECHNOLOGIES INC. (NXTS) Capital Expenditures

2.8 / 5 stars · 68/120 Roast Me

NEXENTIS TECHNOLOGIES INC. Capital Expenditures

NEXENTIS TECHNOLOGIES INC. (NXTS) reported Capital Expenditures of $72.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-13

  • NEXENTIS TECHNOLOGIES INC. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $1.00K.
  • NEXENTIS TECHNOLOGIES INC. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $71.00K.
  • NEXENTIS TECHNOLOGIES INC. payments to acquire property, plant, and equipment for the quarter ending 2022-12-31 was $4.10K, a 92.18% decline year-over-year.
  • NEXENTIS TECHNOLOGIES INC. payments to acquire property, plant, and equipment for the quarter ending 2022-09-30 was $20.63K.
  • NEXENTIS TECHNOLOGIES INC. payments to acquire property, plant, and equipment for fiscal 2025 was $14.00K.
  • NEXENTIS TECHNOLOGIES INC. payments to acquire property, plant, and equipment for fiscal 2022 was $51.69K, a 23.71% decline from fiscal 2021.
  • NEXENTIS TECHNOLOGIES INC. payments to acquire property, plant, and equipment for fiscal 2021 was $67.75K.
  • NEXENTIS TECHNOLOGIES INC. payments to acquire property, plant, and equipment for fiscal 2019 was $23.33K, a 822.38% increase from fiscal 2018.
Period endPayments to Acquire Property, Plant, and Equipment 3 monthPayments to Acquire Property, Plant, and Equipment 6 monthPayments to Acquire Property, Plant, and Equipment 9 monthPayments to Acquire Property, Plant, and Equipment 12 month
2026-06-30$1.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
$72.00K
10-Q · filed 2026-08-13
2026-03-31$71.00K
10-Q · filed 2026-05-14
2025-12-31$14.00K
10-K · filed 2026-03-31
2022-12-31$4.10K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
$24.72K
derived: sum of 2 quarters · filed 2024-04-01
$33.83K
derived: sum of 3 quarters · filed 2024-04-01
$51.69K
10-K · filed 2024-04-01
2022-09-30$20.63K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
$29.73K
derived: sum of 2 quarters · filed 2023-11-14
$47.59K
10-Q · filed 2023-11-14
$99.98K
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30$9.10K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
$26.97K
10-Q · filed 2023-08-14
$79.36K
derived: sum of 3 quarters · filed 2023-08-14
2022-03-31$17.86K
10-Q · filed 2023-05-15
$70.26K
derived: sum of 2 quarters · filed 2023-05-15
2021-12-31$52.39K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27
$67.75K
10-K · filed 2023-03-27
2021-09-30$15.36K
10-Q · filed 2022-11-14
2019-12-31$18.41K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29
$23.33K
10-K · filed 2021-03-29
2019-09-30$4.92K
10-Q · filed 2020-11-12
2018-12-31$2.53K
10-K · filed 2020-03-30

Similar stocks

Stock NameCountryMarket CapPE Ratio
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
Genprex, Inc. (GNPX)United States$0.003B-0.02